May 4th 2024
A review article summarizes the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.
Turning Food Allergy Triggers Into Therapy: A Managed Care Lens on Immunotherapy and Targeted Biologics
1.5 Credits / Immunology
View More
Targeted Therapies for the Management of Eosinophilic Esophagitis Across the Life Cycle: The Role of the Pharmacist in Patient Identification and Optimization, featuring a Pat...
1.5 Credits / Immunology
View More
Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis
June 27, 2024 | 1:00 & 7:00 PM EDT
View More
Managed Care Perspectives on the Burden of Food Allergies and Advances in Treatment
1.5 Credits / Allergy, Immunology
View More
Emerging Concepts and Approaches in the Treatment of Food Allergy: What Managed Care Professionals Need to Know
1.5 Credits / Immunology, Allergy
View More
Regulatory Updates From Around the Globe Provide Hope for Biosimilars
September 9th 2023An approval in Australia and positive recommendations for 2 biosimilars in Europe bring hope for more affordable biologics around the world. However, another settlement for a US ustekinumab biosimilar showcases that some barriers remain.
The Growth of Biosimilars Continues to Create Hope for Lower Drug Costs
September 7th 2023Perhaps the most significant development in the pharmaceutical industry in decades, crops of biosimilars are being approved and are ready for distribution. What lies next, in terms of legislation and the impact on pharmacists, remains to be seen.
Stelara and Enbrel Chosen for IRA Price Negotiation
August 29th 2023Stelara (ustekinumab) and Enbrel (etanercept), 2 originator medications that will face biosimilar competition within the next decade, were among the 10 preliminary drugs chosen for Medicare price negotiation under the Inflation Reduction Act (IRA).
Contributor: The Promise of RA Biosimilars Could Be Realized, but Greater Adoption Rates Are Needed
August 14th 2023Robert Zutaut, RPh, a clinical specialist from McKesson Provider Solutions, quantifies the major barriers to adoption for biosimilars used to treat rheumatoid arthritis (RA) and some major considerations for health systems looking to address them.
Spanish Psoriasis Working Group Revises Guidelines for Biosimilars in Psoriasis
August 10th 2023The Spanish Psoriasis Working Group updated its position on the use of biosimilar medicines in patients with moderate to severe psoriasis, including its views on biosimilars as first-line treatment and nonmedical switching.
BioRationality: The Adulthood of Biosimilars—Global Status and Future of Biosimilars
August 7th 2023Sarfaraz K. Niazi, PhD, gives an overview of the global biosimilar landscape, noting why some countries have biosimilars, including follow-on biologics and unbranded biologics, for certain products and why others do not.
Price Reductions of TNF Inhibitors Across Europe After First and Second Biosimilar Launches
July 29th 2023Authors of a study examined changes in pricing, market share, and utilization of the tumor necrosis factor (TNF)–α inhibitors infliximab, etanercept, and adalimumab as the first and second biosimilars for each molecule were introduced in Europe.
Biosimilar Business News Recap: 3 Biosimilar Application Submissions; Roche Sues Biogen
July 26th 2023Formycon and Celltrion announced the FDA submissions for their aflibercept biosimilars; the European Medicines Agency accepted a marketing authorization application for an ustekinumab biosimilar; and Roche filed suit against Biogen over a tocilizumab biosimilar.
Samsung Bioepis Report Proves Lower Biosimilar Prices Correlate With Greater Market Share
July 19th 2023The second edition of Samsung Bioepis’ Biosimilar Market Report shows strong correlation between biosimilar usage and decreased drug prices, proving that biosimilars are delivering on the promise of savings and price erosion.
Adalimumab Biosimilar Improved Symptoms for up to 48 Weeks in Ankylosing Spondylitis
July 8th 2023In a real-world study in India, patients with ankylosing spondylitis who were treated with the adalimumab biosimilar Exemptia for 10 weeks showed improvements in disease activity that persisted through 48 weeks.
The Age of Adalimumab Is Upon Us: How Stakeholders Can Prepare
June 28th 2023The Center for Biosimilars® provides an updated look on the adalimumab biosimilars that are coming down the US pipeline as well as what stakeholders need to know and how they can prepare ahead of the US launch of 8 adalimumab biosimilars in July 2023.
Meta-Analysis Confirms Bioequivalence of Adalimumab, Infliximab, Etanercept Biosimilars
June 22nd 2023An analysis of 25 studies found adalimumab, infliximab, and etanercept biosimilars were considered just as safe, effective, and tolerable compared with their originators in the treatment of rheumatoid arthritis.
Mark Cuban’s Online Pharmacy Partners With Coherus Biosciences for Humira Biosimilar
June 1st 2023The Mark Cuban Cost Plus Drug Company, an online pharmacy dedicated to increasing access to lower-cost prescriptions, is partnering with Coherus Biosciences to distribute Yusimry, a biosimilar referencing Humira. It’s the first time the pharmacy has added a biosimilar to its list of drugs.